⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086 | 0.95 | ALDH1A1 (0.33) | — | |
| SCHEMBL310609 | 0.93 | ALDH1A1 (0.32) | — | |
| SCHEMBL37824 | 0.90 | — | — | |
| SCHEMBL6253075 | 0.84 | — | — | |
| SCHEMBL19331 | 0.77 | — | — | |
| SCHEMBL2280332 | 0.72 | — | — | |
| SCHEMBL10871578 | 0.72 | — | — | |
| SCHEMBL301587 | 0.72 | — | — | |
| SCHEMBL35293 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL23293782 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2007-07-19 | — | — | US | claimed |
| JP-3553083-B2 | — | — | 2004-08-11 | — | — | JP | claimed |
| EP-0852494-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-15 | — | — | EP | claimed |
| WO-1997009973-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-20 | — | — | WO | claimed |
| WO-2022008383-A1 | ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-01-13 | — | — | WO | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | INDIVIOR UK LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | INDIVIOR UK LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190194225-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR INC. | 2019-06-27 | — | — | US | disclosed |
| EP-1876174-A1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-7279481-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2007-07-19 | — | — | US | disclosed |
| US-6576650-B1 | No central nervous system side effects | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-06-10 | — | — | US | disclosed |
| US-6166039-A | Peripherally active anti-hyperalgesic opiates | REGENTS OF THE UNIV. OF CALIFORNIA (US) | 2000-12-26 | — | — | US | disclosed |
| US-4086234-A | Process for the preparation of tertiary amines | G. D. SEARLE & CO. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4012393-A | ANTIDIARRHEA | G. D. SEARLE & CO. (US) | 1977-03-15 | — | — | US | disclosed |
| US-3996214-A | 5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto | G. D. SEARLE & CO. (US) | 1976-12-07 | — | — | US | disclosed |